|
1
|
Fuller GN and Scheithauer BW: Symposium:
The 2007 revised world health organization (WHO) Classification of
tumors of the central nervous system: newly codified entities.
Brain Pathol. 17:304–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varela M, Ranuncolo SM, Morand A, Lastiri
J, De Kier Joffé EB, Puricelli LI and Pallotta MG: EGF-R and
PDGF-R, but not bcl-2, overexpression predict overall survival in
patients with low-grade astrocytomas. J Surg Oncol. 86:34–40. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kajiwara Y, Yamasaki F, Hama S, Yahara K,
Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of
survivin in astrocytic tumors: Correlation with malignant grade and
prognosis. Cancer. 97:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarkar C, Karak AK, Nath N, Sharma MC,
Mahapatra AK, Chattopadhyay P and Sinha S: Apoptosis and
proliferation: Correlation with p53 in astrocytic tumours. J
Neurooncol. 73:93–100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grenet J, Teitz T, Wei T, Valentine V and
Kidd VJ: Structure and chromosome localization of the human CASP8
gene. Gene. 226:225–232. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boldin MP, Goncharov TM, Goltsev YV and
Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting
protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell.
85:803–815. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muzio M, Chinnaiyan AM, Kischkel FC,
O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M,
Gentz R, et al: FLICE, a novel FADD-homologous ICE/CED-3-like
protease, is recruited to the CD95 (Fas/APO-1) death--inducing
signaling complex. Cell. 85:817–827. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deng Y, Lin Y and Wu X: TRAIL-induced
apoptosis requires Bax-dependent mitochondrial release of
Smac/DIABLO. Genes Dev. 16:33–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blanchard H, Donepudi M, Tschopp M,
Kodandapani L, Wu JC and Grütter MG: Caspase-8 specificity probed
at subsite S(4): Crystal structure of the caspase-8-Z-DEVD-cho
complex. J Mol Biol. 302:9–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hopkins-Donaldson S, Ziegler A, Kurtz S,
Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U and Stahel
R: Silencing of death receptor and caspase-8 expression in small
cell lung carcinoma cell lines and tumors by DNA methylation. Cell
Death Differ. 10:356–364. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKee AE and Thiele CJ: Targeting caspase
8 to reduce the formation of metastases in neuroblastoma. Expert
Opin Ther Targets. 10:703–708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ashley DM, Riffkin CD, Muscat AM, Knight
MJ, Kaye AH, Novak U and Hawkins CJ: Caspase 8 is absent or low in
many ex vivo gliomas. Cancer. 104:1487–1496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jones PA: DNA methylation and cancer.
Oncogene. 21:5358–5360. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galm O, Wilop S, Reichelt J, Jost E,
Gehbauer G, Herman JG and Osieka R: DNA methylation changes in
multiple myeloma. Leukemia. 18:1687–1692. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J,
Guo Y, Yang M, Zhang X, Zhang Q, et al: A six-nucleotide
insertion-deletion polymorphism in the CASP8 promoter is associated
with susceptibility to multiple cancers. Nat Genet. 39:605–613.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen L, Kondo Y, Rosner GL, Xiao L,
Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR,
Einspahr JG, et al: MGMT promoter methylation and field defect in
sporadic colorectal cancer. J Natl Cancer Inst. 97:1330–1338. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen DH, Chan KY, Khoo US, Ngan HY, Xue
WC, Chiu PM, Ip P and Cheung AN: Epigenetic and genetic alterations
of p33ING1b in ovarian cancer. Carcinogenesis.
26:855–863. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Choi YD, Lee JS, Lee JH, Nam JH
and Choi C: Assessment of DNA methylation for the detection of
cervical neoplasia in liquid-based cytology specimens. Gynecol
Oncol. 116:99–104. 2010. View Article : Google Scholar
|
|
20
|
Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W,
Tamboli P, Wood CG and Wu X: Hsa-miR-9 methylation status is
associated with cancer development and metastatic recurrence in
patients with clear cell renal cell carcinoma. Oncogene.
29:5724–5728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SY, Kook MC, Kim YW, Cho NY, Jung N,
Kwon HJ, Kim TY and Kang GH: CpG island hypermethylator phenotype
in gastric carcinoma and its clinicopathological features. Virchows
Arch. 457:415–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kitazawa S, Kitazawa R and Maeda S:
Identification of methylated cytosine from archival formalin-fixed
paraffin-embedded specimens. Lab Invest. 80:275–276. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hopkins-Donaldson S, Bodmer JL, Bourloud
KB, Brognara CB, Tschopp J and Gross N: Loss of caspase-8
expression in highly malignant human neuroblastoma cells correlates
with resistance to tumor necrosis factor-related apoptosis-inducing
ligand-induced apoptosis. Cancer Res. 60:4315–4319. 2000.PubMed/NCBI
|
|
24
|
Hopkins-Donaldson S, Bodmer JL, Bourloud
KB, Brognara CB, Tschopp J and Gross N: Loss of caspase-8
expression in neuroblastoma is related to malignancy and resistance
to TRAIL-induced apoptosis. Med Pediatr Oncol. 35:608–611. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Teitz T, Wei T, Valentine MB, Vanin EF,
Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ:
Caspase 8 is deleted or silenced preferentially in childhood
neuroblastomas with amplification of MYCN. Nat Med. 6:529–535.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saggioro FP, Neder L, Stávale JN,
Paixão-Becker AN, Malheiros SM, Soares FA, Pittella JE, Matias CC,
Colli BO, Carlotti CG Jr, et al: Fas, FasL, and cleaved caspases 8
and 3 in glioblastomas: A tissue microarray-based study. Pathol Res
Pract. 210:267–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
28
|
Gonzalez-Gomez P, Bello MJ, Inda MM,
Alonso ME, Arjona D, Amiñoso C, Lopez-Marin I, de Campos JM, Sarasa
JL, Castresana JS, et al: Deletion and aberrant CpG island
methylation of caspase-8 gene in medulloblastoma. Oncol Rep.
12:663–666. 2004.PubMed/NCBI
|
|
29
|
Knudson AG Jr: Mutation and cancer:
Statistical study of retinoblastoma. Proc Natl Acad Sci USA.
68:820–823. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ebinger M, Senf L, Wachowski O and
Scheurlen W: Promoter methylation pattern of caspase-8,
P16INK4A, MGMT, TIMP-3, and E-cadherin in
medulloblastoma. Pathol Oncol Res. 10:17–21. 2004. View Article : Google Scholar
|
|
31
|
Adams DJ, Waud WR, Wani MC, Manikumar G,
Flowers JL, Driscoll TA and Morgan LR: BACPTDP: A water-soluble
camptothecin pro-drug with enhanced activity in hypoxic/acidic
tumors. Cancer Chemother Pharmacol. 67:855–865. 2011. View Article : Google Scholar
|
|
32
|
Xia S, Lal B, Tung B, Wang S, Goodwin CR
and Laterra J: Tumor microenvironment tenascin-C promotes
glioblastoma invasion and negatively regulates tumor proliferation.
Neuro Oncol. 18:507–517. 2016. View Article : Google Scholar
|
